New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report

Abstract

As mRNA COVID-19 vaccines have become widely available, cases of new-onset glomerular disease after receiving COVID-19 vaccination have been reported. Here, we present a case of kidney biopsy-proven new-onset IgA vasculitis after receiving the mRNA-1273 (Moderna) COVID-19 vaccination. A 47-year-old man with a 10-year medical history of hypertension and hyperuricemia visited our hospital 19 days after receiving an initial mRNA-1273 COVID-19 vaccine injection for purpuric eruption on the legs and dorsal regions of the feet. Although the eruptions spontaneously improved within 5 days, they developed again at 15 days after the second injection. A histopathological examination of skin biopsy specimens was reminiscent of leukocytoclastic vasculitis, though direct immunofluorescence did not indicate IgA deposition within small vessel walls. Urinalysis indicated severe proteinuria (3 +) and occult blood (3 +). Thus, a kidney biopsy was performed and light microscopy revealed mild mesangial expansion, hypercellularity, and endocapillary hypercellularity, with cellular and fibrocellular crescents observed in three and one, respectively, of a total of 15 glomeruli. Immunofluorescence also showed diffuse granular mesangial staining (3 +) for IgA. Histopathological features were consistent with IgA vasculitis. Intravenous methylprednisolone at 1000 mg for 3 days was initiated, followed by oral prednisolone (0.6 mg/kg/day). Over the following 2-week period, serum creatinine level improved from 1.24 to 1.06 mg/dL and proteinuria decreased from 2.98 to 0.36 g/g Cr, though occult blood persisted. Findings in the present case indicate that new-onset IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine can be treated with corticosteroid therapy.

Introduction

Coronavirus disease 2019 (COVID-19) is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain of virus. The first cluster of COVID-19 cases in individuals associated with the Huanan Seafood Wholesale Market in Wuhan, Hubei Province, China, was reported on December 31, 2019 (https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/), then following the worldwide spread of COVID-19, a pandemic was declared by the World Health Organization on March 11, 2020 (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020). As of October 11, 2021, this emerging highly infectious disease had spread to 237,383,711 individuals throughout the world, with 4,842,716 related deaths reported (https://www.who.int/emergencies/diseases/novel-coronavirus-2019) [00:52 am CET, October 12, 2021].

To improve the COVID-19 pandemic situation, two different mRNA vaccines, BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) and mRNA-1273 COVID-19 (Moderna), were authorized by the US Food and Drug Administration on December 11, 2020 and December 18, 2020, respectively. Along with increasing wide availability of those vaccines, cases of vaccine-related new-onset glomerular diseases, including minimal change disease (MCD) [1–5], anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis [6, 7], and immunoglobulin A (IgA) nephropathy [8], that developed after receiving the BNT162b2 mRNA COVID-19 vaccine have been reported. Furthermore, cases of MCD [9], ANCA-associated vasculitis [10, 11], and IgA nephropathy [11–13] have also been reported in individuals who received the mRNA-1273 COVID-19 vaccine.

IgA vasculitis, also referred to as Henoch–Schoenlein purpura, is characterized by immunoglobulin A1 (IgA1)-dominant immune deposits that affect small vessels and often involves the skin, gastrointestinal tract, joints, and kidneys [14], with approximately 40–50% of these cases known to develop simultaneous hematuria and proteinuria [15]. Previous studies have noted occurrence of IgA vasculitis following vaccinations for influenza [16] and hepatitis A [17]. New-onset IgA vasculitis after receiving the BNT162b2 mRNA COVID-19 vaccine has also been reported [18, 19], in which kidney function and urinalysis were normal, as well as a case of new onset IgA vasculitis in an individual who received the mRNA-1273 COVID-19 vaccine [13]. However, a kidney biopsy was not performed for any of those latter three patients, thus no renal histopathological information regarding new-onset IgA vasculitis with kidney involvement after receiving the mRNA COVID-19 vaccine has been made available. Here, we present the first case of kidney biopsy-proven new-onset IgA vasculitis following vaccination with the mRNA-1273 COVID-19 vaccine.

Case report

We treated a 47-year-old male for purpuric eruptions on the legs and dorsal regions of the feet after receiving mRNA-1273 COVID-19 vaccine injections. The patient had a ten-year history of hypertension, for which he was given azilsartan (40 mg) and amlodipine (5 mg), and also of hyperuricemia, with febuxostat (10 mg) prescribed. At the time of onset of hypertension, there was no urinary abnormality. There was no known history of kidney disease including glomerulopathies in the patient or his family members. A purpuric eruption developed on the legs and dorsal regions of the feet 19 days after receiving the first mRNA-1273 COVID-19 vaccination injection, which spontaneously improved at 24 days after receiving that. As scheduled, the second injection was received at 28 days after the first.

Fifteen days following the second vaccination, the patient was referred to the Department of Dermatology of Osaka City University Hospital, and clinical findings showed palpable purpuric papules on the legs and dorsa of the feet (Fig. 1a). On day 16 after the second vaccination, a skin biopsy was performed and histopathological results showed perivascular dermatitis with mixed inflammation, including lymphocytes, neutrophils, and related nuclear dust. Erythrocyte extravasation was also observed in the dermis (Fig. 1b). Although gross hematuria was not noted, urinalysis results showed severe proteinuria (3 +) and occult blood (3 +). The patient was then admitted to the Department of Nephrology at Osaka City University Hospital on day 28.

Fig. 1.

Skin findings. a Palpable purpuric papules were observed on the legs and dorsal regions of the feet on day 15 after the second vaccination. b Skin biopsy results showed a mixture of perivascular inflammation and erythrocyte extravasation in the dermis [hematoxylin and eosin, × 200]

Upon admission, body temperature was 36.7 ℃ and blood pressure was 118/72 mmHg. Physical examination findings of the heart, lungs, abdomen, and nervous system were unremarkable. There was no pitting edema or palpable purpura on the legs or feet dorsal regions. The previously noted eruptions were reported to have spontaneously and completely diminished at 20 days after the second vaccination. Table 1 shows laboratory and urinary data at the time of admission. Urinalysis results presented severe proteinuria (3 +) and occult blood (3 +), and a spot urine protein/creatine ratio of 2.98 g/g Cr. Moreover, urinary analysis of sediment revealed 50–99 red blood cells per high power field (× 400). These results were obviously worse as compared to those obtained at seven days before the first vaccination at his most recent medical checkup, at which time urinalysis showed no proteinuria and only mild occult blood (1 +). Serum creatinine was 0.89 mg/dL and estimated glomerular filtration rate (eGFR) 73.3 mL/min/1.73 m² at that last medical checkup before the first vaccination, while at the time of admission to the Department of Nephology those were 1.24 mg/dL and 50.8 mL/min/1.73 m², respectively. Erythrocyte sedimentation rate, C-reactive protein, complement C3 and C4, and immunoglobulins G, A, and M were normal. Additional serological work-up findings for glomerulonephritis were negative, including hepatitis B and C, and antinuclear and antineutrophil cytoplasmic antibodies. Determination of COVID-19 infection with an RT-PCR examination of saliva, performed as part of the general hospital admission process, showed a negative result.

Table 1.

Clinical and laboratory examination findings at time of admission

Age (years)	47
Body mass index (kg/m2)	27.7
Blood pressure (mmHg)	118/78
Pulse rate (bpm)	78
Features of IgA vasculitis
Gastrointestinal symptoms	–
Arthritis/arthralgia	–
Edema	–
Palpable purpura	–
Serology
Hemoglobin (g/dL)	14.4
Total protein(g/dL)	6.6
Albumin (g/dL)	3.5
Blood urea nitrogen (mg/dL)	12
Creatinine (mg/dL)	1.24
eGFR (mL/min/1.73 m2)	50.8
IgG (mg/dL)	1070
IgA (mg/dL)	349
IgM (mg/dL)	77
CH50 (U/mL)	60 <
C3 (mg/dL)	110
C4 (mg/dL)	28.6
ANA	< 40
MPO-ANCA (EU)	< 0.5
PR3-ANCA (EU)	< 0.5
Cryoglobulin	Negative
Urinalysis
pH	5.5
Blood	3 +
Protein	3 +
Red blood cells (hpf)	50–99
White blood cells (hpf)	1–4
Urinary protein (g/g creatinine)	2.98

ANA, antinuclear antibody; bpm, beats per minute; BUN, blood urea nitrogen; e-GFR, estimated glomerular filtration rate; hpf, high power field; MPO-ANCA, myeloperoxidase-anti-neutrophil cytoplasmic antibodies; PR3-ANCA, proteinase3-anti-neutrophil cytoplasmic antibody

A kidney biopsy was performed on day 29 after the second vaccination and demonstrated severe crescentic glomerulonephritis. Light microscopy revealed nine glomeruli with mild mesangial expansion, hypercellularity, and endocapillary hypercellularity (Fig. 2a), while cellular and fibrocellular crescent were present in three and one, respectively, of a total of 15 glomeruli examined (Fig. 2b). Hemispherical deposits, a characteristic of IgA nephropathy [20], were not observed, and no vasculitis was present in the renal vessel walls. The interstitial component was focally, mainly infiltrated by lymphocytes accompanied by mild fibrosis. Tubular atrophy was presented around the sclerotic glomeruli. Immunofluorescence showed diffuse granular mesangial staining (3 +) for IgA (Fig. 2c). Staining was weakly positive for C3, and negative for IgG as well as other immunoglobulins and complement antibodies. Histopathological features were consistent with IgA vasculitis with an ISKDC classification of IIIb. Although arthralgia, abdominal pain, and IgA deposition within small vessel walls were not observed in the skin biopsy specimen, the EULAR/PRINTO/PRES criteria of IgA vasculitis [21] were fulfilled, as the patient demonstrated palpable purpura, the mandatory criterion, as well as two supporting criteria for kidney involvement in the form of hematuria and histopathological proliferative glomerulonephritis with IgA deposits in the kidney biopsy specimen. Intravenous methylprednisolone at 1000 mg for 3 days was initiated, after which oral prednisolone (0.6 mg/kg/day) was given. Over the following 2-week period, kidney function improved to show a serum creatinine level of 1.06 mg/dL and proteinuria decreased to 0.36 g/g Cr, though occult blood persisted.

Fig. 2.

Kidney biopsy findings. a Mesangial and endocapillary hypercellularity shown by light microscopy [periodic acid-Schiff, × 400]. b Cellular crescents shown by light microscopy [periodic acid-Schiff, × 400]. c Immunofluorescence findings demonstrated 3 + granular global mesangial staining for IgA [× 600]

Discussion

To the best of our knowledge, this is the first case of kidney biopsy-proven new-onset IgA vasculitis with crescentic glomerulonephritis that developed soon after receiving the mRNA-1273 COVID-19 vaccine. In the mRNA-1273 COVID-19 vaccine trial with 30,420 volunteers, macro-purpuric eruption was seen in two in the placebo group and 11 in the vaccine group, while there were no cases of glomerulonephritis [22]. In other studies, two cases (33-year-old male, 40-year-old female) of new-onset IgA vasculitis without kidney involvement after receiving the BNT162b2 mRNA COVID-19 vaccine [18, 19] and one (67-year-old male) of new-onset IgA vasculitis after receiving the RNA-1273 COVID-19 vaccine [13] have been reported In that latter report, the patient showed acute kidney injury and was treated with a 1-week course of prednisolone at 40 mg per day, after which rash, kidney function, and urinalysis findings rapidly improved, though a kidney biopsy was not performed. In the present case, while the skin biopsy results seemed to show leukocytoclastic vasculitis, no fibrin deposition was seen and there were no IgA deposits within small vessel walls observed by direct immunofluorescence. In addition, urinalysis suggested glomerulonephritis. Thus, a kidney biopsy was performed. As expected, the histopathological findings showed proliferative and crescentic glomerulonephritis with IgA deposits. Although the causal relationship between administration of the mRNA-1273 COVID-19 vaccine and onset of IgA vasculitis in this case is uncertain, urinary abnormalities and kidney function deterioration were developed, soon after its vaccination. Following administration of intravenous methylprednisolone and subsequent oral prednisolone therapy, both kidney function and urinary protein were improved.

Several reports of IgA vasculitis following COVID-19 infection have been presented [23–25]. Furthermore, another report by Sugino et al. showed a summary of the characteristics of seven patients with IgA vasculitis following COVID-19 infection, including median age of 23.3 years and a 4:3 ratio of adults to children [26]. In addition to cutaneous purpura, abdominal pain and nephritis were observed in each of those seven cases, while glomerulonephritis was only seen in the adult patients and not identified in the children. Several possible mechanisms related to IgA vasculitis induction by COVID-19 infection have been proposed. A mucosal infection is believed to enhance IL-6 production, which results in aberrant glycosylation including that of IgA1, while an increase in galactose-deficient IgA1 induces immunocomplex deposits in the mesangial region, leading to glomerulonephritis [27]. In addition, bone marrow is the source of increased B lymphocytes producing IgA1 [28, 29]. A COVID-19 infection induces the release of cytokines including IL-1, IL-6, and TNF, which can lead to proliferation and mutation of these IgA1-producing B cells, resulting in IgA vasculitis [26]. However, in the present case of IgA vasculitis, a COVID-19 infection was not present, based on findings of no infectious symptoms and negative results of RT-PCR testing of saliva at the time of admission.

The exact pathogenesis of IgA vasculitis following a COVID-19 vaccination is unknown, though it has been reported that an mRNA COVID-19 vaccine causes antibody production and release of cytokines, which inhibits replication of the SARS-CoV2 virus in patients with IgA nephropathy [30]. Those cytokines may activate IgA1-producing B cells as well, leading to IgA vasculitis. Findings in a previous report of new-onset IgA vasculitis after receiving an mRNA-1273 COVID-19 vaccine suggest that the trigger in predisposed individuals may be an immune response to the spike protein or the mRNA of the mRNA-1273 COVID-19 vaccine [11]. Another report of a patient with IgA vasculitis flare after receiving the mRNA-1273 COVID-19 vaccine suggested a link between increase in anti-SARS-CoV-2 spike IgA and relapse of pre-existing IgA vasculitis [31]. Additional studies are needed to precisely elucidate the pathogenesis of IgA vasculitis following COVID-19 vaccination.

In conclusion, this is the first case of kidney biopsy-proven IgA vasculitis with kidney involvement after receiving an mRNA-1273 COVID-19 vaccination. Although the mRNA-1273 vaccine is effective for prevention of COVID-19 [22], immunologic side-effects including glomerulonephritis are a concern. Several cases of rare but serious adverse reactions have been reported as a part of post-marketing surveillance of COVID-19 vaccines. In the present case, soon after receiving the mRNA-1273 COVID-19 vaccine, urinary abnormalities and kidney function deterioration were developed. Physicians should be aware of glomerulonephritis including IgA vasculitis in patients who have recently undergone administration of an mRNA based COVID-19 vaccine. Should palpable purpura appear following the initial injection, careful follow-up after the second course will be necessary or use of another type of vaccination may be needed to prevent new-onset glomerulonephritis.

Declarations

Conflict of interest

The authors have declared that no conflict of interest exists.

Ethical statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Written informed consent was obtained from the patient for the publication of his clinical data.